Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Synlogic Operating Company, Inc. currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, GANGLE, BRIAN J, within 1 distinct art unit. GANGLE, BRIAN J is the busiest examiner with 1 pending office action. The company's current prosecution is limited to this single interaction, making the specific preferences of this one examiner paramount.
With only 1 pending office action, the portfolio's immediate future depends on the dialogue with GANGLE, BRIAN J. Practitioners must be well-versed in the technical standards of the 1 distinct art unit where the action is being reviewed. This focused workload allows for a very specific prosecution strategy tailored to a single examiner's history and the specialized requirements of their art unit. The outcome of this 1 pending office action will define the company's current standing in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GANGLE, BRIAN J | 1 | 76.8% | +14.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18941023 | MICROORGANISMS ENGINEERED TO REDUCE HYPERPHENYLALANINEMIA | GANGLE, BRIAN J | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18941023 | MICROORGANISMS ENGINEERED TO REDUCE HYPERPHENYLALANINEMIA | GANGLE, BRIAN J | 1645 | §112DP | Non-Final OA | — | Pending | Nov 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSynlogic Operating Company, Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Brian J Gangle has the most, with 1 of Synlogic Operating Company, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
